Targets › GRP78
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.
Endoplasmic reticulum chaperone that plays a key role in protein folding and quality control in the endoplasmic reticulum lumen. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10/ERdj5, probably to facilitate the release of DNAJC10/ERdj5 from its substrate (By similarity). (UniProt, P11021)
Open in Phaseline: the race on GRP78, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bold Therapeutics | BOLD-100 GRP78 expression inhibitor | GRP78 | Phase 1 | Colorectal Cancer | Jul 2027 |
Colorectal Cancer (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.